SISCER Module 5

Part I: Basic Concepts for Binary Markers (Classifiers) and Continuous Biomarkers

July 12-13, 2021

8:30-Noon PT / 11:30-3pm ET

Kathleen Kerr, PhD
Professor of Biostatistics
SISCER Director
University of Washington

Module Overview

- Part I: Introductory concepts
- Part II: Evaluating Risk Models
- Part III: Evaluating the Incremental Value of New Biomarkers
- Part IV: Guidance on Developing Risk Models
- Part V: Setting goals for early phase biomarker research
- Part VI: Prognostic vs. Predictive Biomarkers
- biomarker analysis in R (short demo)

Module Overview

- The focus of this module is concepts rather than statistical details
  - we will not derive hypothesis tests or distributional results
  - we will examine some mathematical expressions as we explore concepts

Misconceptions about Biomarkers and Risk Models

- A large odds ratio implies that a biomarker is useful for prediction.
- A data analyst can identify the optimal threshold from an ROC curve.
- A data analyst can identify the optimal risk threshold from a Decision Curve.
- The best biomarker to improve a risk model is the one with strongest association with the outcome.
- To improve prediction, a new biomarker should be independent of existing predictors
- To assess whether to add new biomarker to a risk model, multiple stages of hypothesis testing are needed.
- We can often use biomarkers to identify which patients will benefit from treatment.

Part I Topics

- Motivating and illustrative examples
- True and false positive rates (TPR, FPR)
- Predictive values (PPV, NPV)
- ROC curves and area under the curve (AUC)
- Risk models
- What is “personal risk”?

Part 1 Overview

- Some examples
- To start: 1 marker X is binary (a “test”)
- We then move on: 1 marker X is continuous
- Multiple markers X, Y, …, and risk model P(bad outcome | X, Y, …)

What is a Marker?

- DEF: a quantitative or qualitative measure that is potentially useful to classify individuals for current or future status
  - current → diagnostic marker
  - future → prognostic marker
- Includes biomarkers measured in biological specimens
- Includes imaging tests, sensory tests, clinical signs and symptoms, risk factors

What is the purpose of a classifier or risk prediction tool?

- To inform subjects about risk
- To help make medical decisions
  - Often: identify individuals with high risk – individuals at high risk of a clinical event have the greatest potential to benefit from an intervention that could prevent the event
  - Sometimes: identify individuals with low risk who are unlikely to benefit from an intervention
- To enrich a clinical trial with “high risk” patients

Terminology and Notation

- "case" or "event" is an individual with the (bad) outcome
- "control" or "non-event" is an individual without the outcome

case	control
D=1	D=0
D	$\overline{D}$
D	N

Terminology and Notation

- X, Y = potential predictors of D (biomarkers, demographic factors, clinical characteristics)
- Often: X is "standard" predictor(s) and Y is a new biomarker under consideration
- risk(X) = r(X) = P(D=1 | X)
  - risk(X,Y) = r(X,Y) = P(D=1 | X, Y)
- prevalence = P(D=1) = ρ ("rho")

What is risk(X)?

- risk(x) ≡ P(D=1 | X=x) is the frequency of events/disease among the group with X = x

- Risk is simply a population frequency. "Personal risk" is not completely personal!
  - Will return to this at the end of Part I

Example: Coronary Artery Surgery Study (CASS)

- 1465 men undergoing coronary arteriography for suspected coronary heart disease
- Arteriography is the “gold standard” measure of coronary heart disease
  - Evaluates the number and severity of blockages in arteries that supply blood to the heart
- Simple cohort study
- Possible marker: exercise stress test (EST)
- Possible marker: chest pain history (CPH)

Example: Breast Cancer Biomarkers

- Women with positive mammograms undergo biopsy, the majority turn out to be benign lesions
- Provides motivation to develop serum biomarker to reduce unnecessary biopsies (EDRN – early detection research network)

Example: Pancreatic Cancer Biomarkers

- 141 patients with either pancreatitis (n=51) or pancreatic cancer (n=90)
- Serum samples
- Two candidate markers:
  - A cancer antigen CA-125
  - A carbohydrate antigen CA19-9
- Which marker is better at identifying cancer?
- Is either marker good enough to be useful?

Wieand, Gail, James, and James *Biometrika* 1989

Example: Cardiovascular Disease

- Framingham study
- D = CVD event
- Y = high density lipoprotein
- X = demographics, smoking, diabetes, blood pressure, total cholesterol
- n = 3264, n_D=183

Simulated Data

- Artificial data are useful for exploring/illustrating methodology
- Next: artificial datasets we will use to illustrate some methods
  - Simulated data on DABS website
  - Simulated data from R packages *rmda* (risk model decision analysis) and *BioPET*
  - Normal and MultiNormal biomarker model

Example: Simulated data on DABS website

- n = 10,000, n_D=1017
- Y = continuous, 1-dimensional
- X = continuous, 1-dimensional
- Search “Pepe DABS” or http://research.fhcrc.org/diagnostic-biomarkers-center/
  - “simulated risk reclassification dataset”

Example: Simulated data in R packages

- n = 500, n_D=60
- X = sex, smoking status, Marker1
- Y = Marker2
- These simulated data appear in software demo (not in module notes)

Normal Model with 1 Marker

- Biomarker X Normally distributed in controls and in cases

$$X \sim N(0,1) \text{ in controls}$$

$$X \sim N(\mu,1) \text{ in cases}$$



Distribution of X when μ=1

Multivariate Normal Model with 2 Markers (Bivariate Normal)

- Biomarkers (X_1, X_2) are bivariate Normally distributed in controls and in cases

$$\vec{X} \sim MVN(\vec{0}, \Sigma) \text{ in controls}$$

$$\vec{X} \sim MVN(\vec{\mu}, \Sigma) \text{ in cases}$$

$$\Sigma = \begin{bmatrix} 1 & r \\ r & 1 \end{bmatrix}$$

In these examples X_1 and X_2 each have mean (0,0) in controls and mean (1,2) in cases. We can picture marker data in 2-dimensional space.



- Biomarkers (X_1, X_2) are bivariate Normally distributed in controls and in cases

$$\vec{X} \sim MVN(\vec{0}, \Sigma) \text{ in controls}$$

$$\vec{X} \sim MVN(\vec{\mu}, \Sigma) \text{ in cases}$$

- This data model is useful in research because the logistic regression model holds for each marker **and** for both markers together.

  logit P(D=1| X_1) is linear in X_1

  logit P(D=1| X_2) is linear in X_2

  logit P(D=1|X_1, X_2) is linear in X_1 and X_2

Generalization: Multivariate Normal Model

- Biomarkers (X_1, X_2, …, X_k) are multivariate Normally distributed in controls and in cases

$$\vec{X} \sim MVN(\vec{0}, \Sigma) \text{ in controls}$$

$$\vec{X} \sim MVN(\vec{\mu}, \Sigma) \text{ in cases}$$

- The linear logistic model holds for every subset of markers

QUANTIFYING CLASSIFICATION ACCURACY (BINARY MARKER OR “TEST”)

Terminology

- D = outcome (disease, event)
- Y = marker (test result)

	D=0	D=1
Y=0	true negative	false negative
Y=1	false positive	true positive

Terminology

- D = outcome (disease, event)
- Y = marker (test result)



Terminology

TPR = true positive rate = P[Y=1|D=1] = sensitivity

FPR = false positive rate = P[Y=1|D=0] = 1-specificity

FNR = false negative rate = P[Y=0|D=1] = 1-TPR

TNR = true negative rate = P[Y=0|D=0] = 1-FPR

Ideal test: FPR=0 and TPR=1

- (FPR, TPR)



benefit

Later, we will consider the benefits of identifying a true positive

cost

Later, we will consider the costs associated with false positives

Coronary Artery Surgery Study (CASS)

Coronary Artery Disease

Exercise Stress Test	D=0	D=1
Y=0	327	208
Y=1	115	815
	442	1023

FPR=115/442=26%

TPR=815/1023=80%

What about Odds Ratios?

- Odds ratios are very popular:
  - Because logistic regression is popular
  - Odds Ratio estimable from case-control study
  - OR≈relative risk for rare outcome
- $OR = \frac{TPR\,(1-FPR)}{FPR\,(1-TPR)}$
- Good classification (high TPR and low FPR) → large odds ratio
- However, large odds ratio does NOT imply good classification!

Good classification → large odds ratio

E.g., TPR=0.8, FPR=0.10

$$OR = \frac{0.8 \times 0.9}{0.1 \times 0.2} = 36$$

Coronary Artery Surgery Study (CASS)

Coronary Artery Disease

Exercise Test	D=0	D=1
Y=0	327	208
Y=1	115	815
	442	1023

FPR=115/442=26%

TPR=815/1023=80%

OR ≈ 11.1

OR is large but classification performance is not exceptional.

large odds ratio does NOT imply good classification!

Pepe et al, American Journal of Epidemiology 2004; 159:882-890.



FIGURE 1. Correspondence between the true-positive fraction (TPF) and the false-positive fraction (FPF) of a binary marker and the odds ratio. Values of (TPF, FPF) that yield the same odds ratio are connected.

- Need to report *both* FPR and TPR
- Collapsing into one number (e.g., OR) is not sufficient
  - important information is lost

Misclassification Rate

MR = error rate = $P(Y \neq D)$

$= P(Y=0, D=1) + P(Y=1, D=0)$

$= \rho(1\text{-}TPR)+(1- \rho)FPR$

- ρ is the prevalence $P(D=1)$
- only appropriate if the cost of false positives equals the cost of false negatives
- seldom appropriate in biomedical applications

Misclassification Rate

- There are two kinds of wrong decisions and the MR equates these.
  - Similarly, model “accuracy”, which is 1–MR, equates the two types of errors.
- In order to be clinically relevant we must consider the harms of each kind of error
  - Part II

- FPR, TPR condition on true status (D)
- they address the question: “to what extent does the biomarker reflect true status?”

Predictive Values

Positive predictive value PPV=P(D=1|Y=1)

Negative predictive value NPV=P(D=0|Y=0)

- condition on biomarker results (Y)
- address the question: "Given my biomarker value is Y, what is the chance that I have the disease?" This is the question of interest for patients and clinicians when interpreting the result of a biomarker or test

Predictive Values

PPV and NPV are functions of TPR and FPR *and* the prevalence ρ

$$PPV = \frac{\rho\, TPR}{\rho\, TPR + (1-\rho)FPR}$$

$$NPV = \frac{(1-\rho)(1-FPR)}{(1-\rho)(1-FPR) + \rho(1-TPR)}$$

- TPR, FPR are properties of a test, but PPV, NPV are properties of *a* test *in a population*
- For low prevalence conditions, PPV tends to be low, even with very sensitive tests

Predictive Values - Example

A serious disease affects 1 in 10,000 in a population.

A company markets a screening test as “98% accurate” because both sensitivity and specificity have been estimated to be 98%.

Those who test positive are recommended to undergo an invasive procedure for definitive diagnosis.

Should there be general screening for the patient population?

Predictive Values - Example

Disease affects 1 in 10,000 in a the population.

Test has sensitivity=specificity=98%.

A person from the population tests negative. What is the probability that person is truly not diseased?

A person from the population tests positive. What is the probability that person has the disease?

Predictive Values - Example

Disease affects 1 in 10,000 in a the population.

Test has sensitivity=specificity=98%.

What is the probability that person who tests negative is truly not diseased?

What is the probability that person who tests positive truly has the disease?

Predictive Values - Example

A serious disease affects 1 in 10,000 in a the relevant population.

A company markets a screening test as “98% accurate” because both sensitivity and specificity have been estimated to be 98%.

Those who test positive are recommended to undergo an invasive procedure for definitive diagnosis.

Should there be general screening for the patient population?

NPV = ?

PPV = ?

MATH

Coronavirus Antibody Tests Have a Mathematical Pitfall

The accuracy of screening tests is highly dependent on the infection rate

By Sarah Lewin Frasier | Scientific American July 2020 Issue

READ THIS NEXT

SPONSORED CONTENT
New Kavli Prize Winners Reveal Their Secrets
June 11, 2020

WELLNESS
Fiber 2.0--Fiber's New Science of Healt Boosting Benefits
1 hour ago — Nutrition Diva Monica Reinagel

False Discovery Rate

False Discovery Rate FDR=P(D=0|Y=1)

=1 – PPV

"False Positive Rate" and "False Discovery Rate" sound similar, but they are very different

- FPR: among all those who are not diseased, how many were called positive
- FDR: among all those called positive, how many were not actually diseased.
- We will not use or further discuss FDR.

CONTINUOUS MARKERS: ROC CURVES

Motivation

- Most biomarkers are continuous

Convention

- Assume larger Y more indicative of disease
  - otherwise replace Y with -Y
- Formally: $P(D=1 \mid Y)$ increasing in Y

Receiver Operating Characteristic (ROC) Curve

- generalizes (FPR, TPR) to continuous markers
- considers rules based on thresholds "$Y \geq c$"
  - makes sense if $P(D=1|Y)$ increasing in Y
- $TPR(c)=P(Y \geq c \mid D=1)$
- $FPR(c)=P(Y \geq c \mid D=0)$
- $ROC(\cdot)=\{FPR(c), TPR(c) ; c \text{ in } (-\infty,\infty)\}$



Receiver Operating Characteristic Curve (ROC Curve)

Each point on the ROC curve corresponds to a threshold for declaring “marker-positive.”




A
Controls
Cases
Marker Values


1
0.8
0.6
0.4
0.2
0
True Positive Rate
A
0
0.5
1
False Positive Rate


B
Controls
Cases
Marker Values


1
0.8
0.6
0.4
0.2
0
B
True Positive Rate
0
0.5
1
False Positive Rate


C
Controls
Cases
Marker Values


C
True Positive Rate
False Positive Rate
0
0.2
0.4
0.6
0.8
1
0
0.5
1


C
B
A
Controls
Cases
Marker Values


1
0.8
0.6
0.4
0.2
0
0
0.5
1
True Positive Rate
False Positive Rate
C
B
A

Properties of ROC curves

- non-decreasing from (0,0) to (1,1) as threshold decreases from c=∞ to c= −∞
- *ideal* marker has control distribution completely disjoint from case distribution; ROC through (0,1)
- *useless* marker has ROC equal to 45 degree line
- doesn't depend on scale of Y: invariant to monotone increasing transformations of Y
- puts different markers on a common relevant scale
- shows entire range of possible performance

Pancreatic cancer biomarkers (Wieand et al 1989)




ROC curves for pancreatic cancer biomarkers
True positive rate
False positive rate
0.0
0.2
0.4
0.6
0.8
1.0
CA 19-9
CA 125

CA-19-9 appears to be the more accurate diagnostic biomarker for pancreatic cancer



- for most FPR, CA-19-9 has the better corresponding TPR
- for most TPR, CA-19-9 has the better corresponding FPR

ROC limitations

- ROC curve summarizes (FPR, TPR) across all possible cut-points for the continuous marker
  - Alternatively, (specificity, sensitivity)
  - Aids in assessing: How well can the marker discriminate between controls and cases ?
- While useful, ROC curves do not contain crucial information
  - Prevalence
  - Value of TP, Cost of FP
- →There is no way to determine an optimal cut-point from an ROC curve

Summarizing ROC Curves: AUC

- AUC is Area under ROC curve
- AUC = $\int_0^1 ROC(t)\, dt$ = average(TPR)
  - average is uniform over (0,1)
- Common summary of ROC curve
  - sometimes called the c-index or c-statistic
- ideal marker: AUC=1.0
- useless marker: AUC=0.5
- A single number summary of a curve is necessarily a crude summary
- Commonly used to compare biomarkers

AUC: probabilistic interpretation

- For a randomly selected case D and a randomly selected control N,

$$AUC = P(Y_D > Y_N)$$

  - Provides an interpretation for AUC beyond "area under ROC curve"
- AUC is interpretable, but its interpretations show that AUC is not clinically meaningful

RISK PREDICTION

Risk Model: Huntington's Disease

- Huntington's Disease is caused by the gene *HTT* on human chromosome 4. There is a CAG segment that is repeated 10-35 times in non-diseased individuals. If the segment is repeated 36-120+ times, a person develops* Huntington's Disease in middle-age. The genetic abnormality is dominant ─ one abnormal gene causes disease.
  - *40+ times: always develop HD
  - *36-39 times: might not develop HD (ignoring this small possibility)

Risk Model: Huntington's Disease

- Relevant Population: Individuals with a biological parent who has Huntington's Disease
- Within this population, an individual has a 50% chance of developing HD depending on whether he or she inherited the abnormal or normal version of the gene from the affected parent.
- P(D) = ½ = ρ in this population.

Risk Model: Huntington's Disease

- An individual can choose to have their *HTT* gene genotyped. Say HTT=0 means 0 copies of abnormal gene; HTT=1 means 1 copy of abnormal gene.
- P(D | HTT=0)=0% ; P(D | HTT=1)=100%.
- The marker HTT *stratifies* the patient population (risk=50%) into the subgroup with 0% risk and the subgroup with 100% risk.

Risk model

- risk prediction model – gives a risk based on a marker value or a combination of markers
- Predicted risks are in the interval [0,1] and interpreted as probabilities
- It is rare that a risk model is definitive like the HD example
  - In fact, because the genetic test for Huntington's Disease is definitive, we might not think about it as a risk model

Risk model examples

- Most risk models combine information from multiple risk factors
- E.g., Gail model for breast cancer risk
  - for use in women with no history of breast cancer
  - Estimates 5-year risk of breast cancer based on current age, age at menarche, age at first birth, family history, race.
- E.g., Framingham CHD risk score
  - Estimates risk of CHD based on age, sex, smoking status, total and HDL cholesterol, blood pressure

Risk model examples

- E.g. STS risk score for dialysis following cardiac surgery is formed via:
  - STS risk score = $f(\alpha + \beta_1$ Age + β_2 Surgery Type + β_3 Diabetes + β_4 MI Recent + β_5 Race + β_6Chronic Lung Disease + β_7 Reoperation + β_8NYHA Class + β_9 Cardiogenic Shock+ β_{10}Last Serum Creatinine)

What is “personal risk”?

- Recall: risk(x) ≡ P(D=1 | X=x) is the frequency of events among the group with marker values x

- “Personal risk” is not completely personal!
  - (next example)

What is “personal risk”?

- Suppose the prevalence of D in “Population A” is 1%
  - Without any additional information, the only valid risk prediction instrument is to assign everyone in the population risk=1%
- Suppose we have a marker X that tends to be higher in cases than controls



Distribution of marker X in controls (blue) and cases (red)

What is “personal risk”?

- Alice is an individual in Population A. Alice has X=1.
- We can calculate Alice’s risk(X=1)≈1.6%
  - calculation uses Bayes’ rule



Distribution of marker X in controls (blue) and cases (red)

What is “personal risk”?

- Suppose the marker acts exactly the same in Population B. The only difference between Populations A and B is that B has prevalence=10%.
- Betty, an individual in Population B, has X=1. Betty’s risk is ≈15.5%



Distribution of marker X in controls (blue) and cases (red)

What is “personal risk”?

- “Personal risk” is a term that is prone to be misconstrued
- Risk is personal in the sense that it is calculated from personal characteristics
- However, personal risk is not completely divorced from population characteristics. The previous example shows that the population (specifically, the population prevalence) affects “personal” risk.

What is “personal risk”?

- Occasionally one hears mention of estimating a person’s “individual risk” or “true personal risk.”
- Frequentist statisticians cannot really claim to do so.
- One might claim John’s “true risk” of a heart attack in the next 5 years is 7%. But we can only observe John *having* or *not having* a heart attack in the next 5 years. I cannot observe John having a heart attack in 7% of 5-year periods from now.
- The best I can objectively claim is that “among people with John’s characteristics, 7% will have a heart attack in the next 5 years.”
  - More than one way to define “people like John.”

Summary of Part I

- Example datasets
- FPR (1 – specificity), TPR (sensitivity)
- PPV, NPV
  - function of FPR, TPR and disease prevalence
- ROC curves
- AUC
  - geometric interpretation as area under curve
  - probability interpretation
- A risk model gives population frequencies:
  $risk(X)=P(D=1|X)$

Misconceptions about Biomarkers and Risk Models

- A large odds ratio implies that a biomarker is useful for prediction. ✖
- A data analyst can identify the optimal threshold from an ROC curve. ✖
- A data analyst can identify the optimal risk threshold from a Decision Curve.
- The best biomarker to improve a risk model is the one with strongest association with the outcome.
- To improve prediction, a new biomarker should be independent of existing predictors
- To assess whether to add new biomarker to a risk model, multiple stages of hypothesis testing are needed.
- We can often use biomarkers to identify which patients will benefit from treatment.